Unknown

Dataset Information

0

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma.


ABSTRACT: BACKGROUND:Oxaliplatin-capecitabine (OxCap) and carboplatin-paclitaxel (CarPac) based neo-adjuvant chemoradiotherapy (nCRT) have shown promising activity in localised, resectable oesophageal cancer. PATIENTS AND METHODS:A non-blinded, randomised (1:1 via a centralised computer system), 'pick a winner' phase II trial. Patients with resectable oesophageal adenocarcinoma ? cT3 and/or ? cN1 were randomised to OxCapRT (oxaliplatin 85 mg/m2 day 1, 15, 29; capecitabine 625 mg/m2 bd on days of radiotherapy) or CarPacRT (carboplatin AUC2; paclitaxel 50 mg/m2 day 1, 8, 15, 22, 29). Radiotherapy dose was 45 Gy/25 fractions/5 weeks. Both arms received induction OxCap chemotherapy (2 × 3 week cycles of oxaliplatin 130 mg/m2 day 1, capecitabine 625 mg/m2 bd days 1-21). Surgery was performed 6-8 weeks after nCRT. Primary end-point was pathological complete response (pCR). Secondary end-points included toxicity, surgical morbidity/mortality, resection rate and overall survival. STATISTICS:Based on pCR ? 15% not warranting future investigation, but pCR ? 35% would, 76 patients (38/arm) gave 90% power (one-sided alpha 10%), implying that arm(s) having ?10 pCR out of first 38 patients could be considered for phase III trials. ClinicalTrials.gov: NCT01843829. Funder: Cancer Research UK (C44694/A14614). RESULTS:Eighty five patients were randomised between October 2013 and February 2015 from 17 UK centres. Three of 85 (3.5%) died during induction chemotherapy. Seventy-seven patients (OxCapRT = 36; CarPacRT = 41) underwent surgery. The 30-d post-operative mortality was 2/77 (2.6%). Grade III/IV toxicity was comparable between arms, although neutropenia was higher in the CarPacRT arm (21.4% versus 2.6%, p = 0.01). Twelve of 41 (29.3%) (10 of first 38 patients) and 4/36 (11.1%) achieved pCR in the CarPacRT and OxcapRT arms, respectively. Corresponding R0 resection rates were 33/41 (80.5%) and 26/36 (72.2%), respectively. CONCLUSION:Both regimens were well tolerated. Only CarPacRT passed the predefined pCR criteria for further investigation.

SUBMITTER: Mukherjee S 

PROVIDER: S-EPMC5341738 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma.

Mukherjee Somnath S   Hurt Christopher Nicholas CN   Gwynne Sarah S   Sebag-Montefiore David D   Radhakrishna Ganesh G   Gollins Simon S   Hawkins Maria M   Grabsch Heike I HI   Jones Gareth G   Falk Stephen S   Sharma Ricky R   Bateman Andrew A   Roy Rajarshi R   Ray Ruby R   Canham Jo J   Griffiths Gareth G   Maughan Tim T   Crosby Tom T  

European journal of cancer (Oxford, England : 1990) 20170208


<h4>Background</h4>Oxaliplatin-capecitabine (OxCap) and carboplatin-paclitaxel (CarPac) based neo-adjuvant chemoradiotherapy (nCRT) have shown promising activity in localised, resectable oesophageal cancer.<h4>Patients and methods</h4>A non-blinded, randomised (1:1 via a centralised computer system), 'pick a winner' phase II trial. Patients with resectable oesophageal adenocarcinoma ≥ cT3 and/or ≥ cN1 were randomised to OxCapRT (oxaliplatin 85 mg/m<sup>2</sup> day 1, 15, 29; capecitabine 625 mg/  ...[more]

Similar Datasets

| S-EPMC4329217 | biostudies-literature
| S-EPMC8330696 | biostudies-literature
| S-EPMC6598683 | biostudies-literature
| S-EPMC4176450 | biostudies-literature
| S-EPMC4872363 | biostudies-literature
| S-EPMC5210022 | biostudies-literature
| S-EPMC4707116 | biostudies-literature
| S-EPMC10322142 | biostudies-literature
| S-EPMC4791180 | biostudies-literature
| S-EPMC9019849 | biostudies-literature